227 related articles for article (PubMed ID: 28155048)
1. Patient versus general population health state valuations: a case study of non-specific low back pain.
van Dongen JM; van denBerg B; Bekkering GE; van Tulder MW; Ostelo RWJG
Qual Life Res; 2017 Jun; 26(6):1627-1633. PubMed ID: 28155048
[TBL] [Abstract][Full Text] [Related]
2. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
3. Experience-based health state valuation using the EQ VAS: a register-based study of the EQ-5D-3L among nine patient groups in Sweden.
Teni FS; Burström K; Devlin N; Parkin D; Rolfson O;
Health Qual Life Outcomes; 2023 Apr; 21(1):34. PubMed ID: 37038172
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the EQ-5D-3L and 5L versions in low back pain patients.
Garratt AM; Furunes H; Hellum C; Solberg T; Brox JI; Storheim K; Johnsen LG
Health Qual Life Outcomes; 2021 May; 19(1):155. PubMed ID: 34049574
[TBL] [Abstract][Full Text] [Related]
5. Can EQ-5D-3L utility values of low back pain patients be validly predicted by the Oswestry Disability Index for use in cost-effectiveness analyses?
Pellekooren S; Ben ÂJ; Bosmans JE; Ostelo RWJG; van Tulder MW; Maas ET; Huygen FJPM; Oosterhuis T; Apeldoorn AT; van Hooff ML; van Dongen JM
Qual Life Res; 2022 Jul; 31(7):2153-2165. PubMed ID: 35040002
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-life valuations of advanced breast cancer by New Zealand women.
Milne RJ; Heaton-Brown KH; Hansen P; Thomas D; Harvey V; Cubitt A
Pharmacoeconomics; 2006; 24(3):281-92. PubMed ID: 16519549
[TBL] [Abstract][Full Text] [Related]
7. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Little MH; Reitmeir P; Peters A; Leidl R
Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
[TBL] [Abstract][Full Text] [Related]
8. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
Kiadaliri AA; Eliasson B; Gerdtham UG
Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
[TBL] [Abstract][Full Text] [Related]
9. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
Stevens K; Brazier J; Rowen D
Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
[TBL] [Abstract][Full Text] [Related]
10. Using EQ-5D Data to Measure Hospital Performance: Are General Population Values Distorting Patients' Choices?
Gutacker N; Patton T; Shah K; Parkin D
Med Decis Making; 2020 May; 40(4):511-521. PubMed ID: 32486958
[No Abstract] [Full Text] [Related]
11. A comparison of injured patient and general population valuations of EQ-5D health states for New Zealand.
Wilson R; Hansen P; Langley J; Derrett S
Health Qual Life Outcomes; 2014 Feb; 12():21. PubMed ID: 24548314
[TBL] [Abstract][Full Text] [Related]
12. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff].
Lamers LM; Stalmeier PF; McDonnell J; Krabbe PF; van Busschbach JJ
Ned Tijdschr Geneeskd; 2005 Jul; 149(28):1574-8. PubMed ID: 16038162
[TBL] [Abstract][Full Text] [Related]
13. The social tariff of EQ-5D is not adequate to assess quality of life in patients with low back pain.
Zamora J; Kovacs F; Abraira V; Fernández C; Lázaro P;
Qual Life Res; 2007 Apr; 16(3):523-31. PubMed ID: 17111230
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys.
Martí-Pastor M; Pont A; Ávila M; Garin O; Vilagut G; Forero CG; Pardo Y; Tresserras R; Medina-Bustos A; Garcia-Codina O; Cabasés J; Rajmil L; Alonso J; Ferrer M
Popul Health Metr; 2018 Aug; 16(1):14. PubMed ID: 30115092
[TBL] [Abstract][Full Text] [Related]
17. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
[TBL] [Abstract][Full Text] [Related]
18. Assessing quality of life in a clinical study on heart rehabilitation patients: how well do value sets based on given or experienced health states reflect patients' valuations?
Leidl R; Schweikert B; Hahmann H; Steinacker JM; Reitmeir P
Health Qual Life Outcomes; 2016 Mar; 14():48. PubMed ID: 27005466
[TBL] [Abstract][Full Text] [Related]
19. Performance of the EQ-5D in patients with irritable bowel syndrome.
Bushnell DM; Martin ML; Ricci JF; Bracco A
Value Health; 2006; 9(2):90-7. PubMed ID: 16626412
[TBL] [Abstract][Full Text] [Related]
20. Valuation of the EQ-5D-3L in Russia.
Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
